A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) Read more about A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD)
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease Read more about A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
"A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" Read more about "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2"
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) Read more about A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)
The study of efficacy and saftey of Rituximab in treatment of resistant glomerulonephritis Read more about The study of efficacy and saftey of Rituximab in treatment of resistant glomerulonephritis
Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer Read more about Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer
Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency Read more about Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency
The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks Read more about The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks
Effects of Add on Pegylated Interferon therapy in patients of Chronic hepatitis B in maintained response with ongoing nucleos(t)ide analogues ; A multicenter, prospective, randomized open label trial. Read more about Effects of Add on Pegylated Interferon therapy in patients of Chronic hepatitis B in maintained response with ongoing nucleos(t)ide analogues ; A multicenter, prospective, randomized open label trial.
Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 Read more about Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4
